These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3181249)

  • 1. Aclarubicin in advanced thyroid cancer: a phase II study.
    Samonigg H; Hossfeld DK; Spehn J; Fill H; Leb G
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1271-5. PubMed ID: 3181249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metastatic thyroid cancer: sudden death following aclarubicin therapy].
    Langsteger W; Lind P; Beham A; Klima G; Eber B; Költringer P; Eber O
    Klin Wochenschr; 1989 Apr; 67(7):393-7. PubMed ID: 2747139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An effective salvage regimen with aclarubicin for daunorubicin-resistant acute non-lymphocytic leukemia in children.
    Nibu K; Yanai F; Okamura J; Ikuno Y; Tasaka H; Matsuzaki A; Inada H; Eguchi H; Sakai R; Koga H
    Pediatr Hematol Oncol; 1995; 12(3):251-8. PubMed ID: 7640178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel approach to the study of analogs.
    Natale RB; Cody RL; Simon MS; Wheeler RH
    Cancer Chemother Pharmacol; 1993; 31(6):485-8. PubMed ID: 8453689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aclacinomycin A in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Karanes C; Crowley J; Sawkar L; Tranum BL; Hicks WJ; Bonnet JD; Dabich L; Dana BW; Salmon S
    Invest New Drugs; 1990 Feb; 8(1):101-4. PubMed ID: 2188925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer.
    Jensen PB; Larsen SK; Stilbo I
    Cancer Chemother Pharmacol; 1992; 30(3):219-20. PubMed ID: 1321008
    [No Abstract]   [Full Text] [Related]  

  • 7. [A clinical study of the radiosensitization of aclarubicin].
    Miyamoto T; Morita S; Asakawa H; Koyama T; Dokiya T; Kondo M; Yamashita T; Ohkawa T; Kanehira T
    Gan No Rinsho; 1989 Mar; 35(4):472-6. PubMed ID: 2654441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of aclacinomycin A (ACM-A, NSC208734) in patients with metastatic colorectal cancer.
    Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey G
    Am J Clin Oncol; 1983 Apr; 6(2):187-90. PubMed ID: 6572470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
    Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
    Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias.
    Mitrou PS; Kuse R; Anger H; Herrmann R; Bonfert B; Pralle H; Thiel E; Westerhausen M; Mainzer K; Bartels H
    Eur J Cancer Clin Oncol; 1985 Aug; 21(8):919-23. PubMed ID: 3862584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined chemotherapy with cisplatin and aclarubicin hydrochloride for metastatic brain tumors].
    Tanaka T; Kobayashi T; Kida Y
    No Shinkei Geka; 1988 Jan; 16(1):23-8. PubMed ID: 3163105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical review of aclacinomycin A in Japan.
    Ota K
    Drugs Exp Clin Res; 1985; 11(1):17-21. PubMed ID: 3869800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
    Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M
    Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of aclarubicin in acute myeloblastic leukemia.
    Case DC; Ervin TJ; Boyd MA; Bove LG; Sonneborn HL; Paul SD
    Am J Clin Oncol; 1987 Dec; 10(6):523-6. PubMed ID: 3479891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
    Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aclarubicin: experimental and clinical experience.
    Röthig HJ; Kraemer HP; Sedlacek HH
    Drugs Exp Clin Res; 1985; 11(2):123-5. PubMed ID: 3915280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes.
    Xu WL; Jin J; Qian WB
    Chin Med J (Engl); 2010 Jan; 123(1):108-10. PubMed ID: 20137586
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II evaluation of aclacinomycin-A in patients with adenocarcinoma and large cell carcinoma of the lung.
    Tapazoglou E; Haas CD; Samson MK; Baker LH; Pazdur R
    Am J Clin Oncol; 1985 Aug; 8(4):298-301. PubMed ID: 3002165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of aclarubicin in patients with lymphoma.
    Case DC; Boyd MA; Hayes DM
    Cancer Treat Rep; 1985 Nov; 69(11):1315-6. PubMed ID: 3867405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.